Infinity Pharmaceuticals Inc. (INFI): Infinity Pharmaceuticals Management ... Seeking Alpha This open label single-arm study is designed to evaluate the safety and efficacy of IPI-145 administered 25 mg BID in approximately 120 patients with Indolent Lymphoma, whose disease is refractory to radio immunotherapy or to both rituximab and ... |
